Drugs / HP518
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05252364 | Dec 2021 → Jan 2024 | prostate carcinoma | Hinova Pharmaceuticals Aus Pty Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06155084 | Dec 2023 → Mar 2026 overdue | prostate carcinoma | Hinova Pharmaceuticals Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HP518 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05252364 ↗ |
| Route | Oral | “HP518 once daily orally” PMID 40289067 ↗ Apr 2025 |
| Target | AR | “HP518 is an oral PROteolysis TArgeting Chimera (PROTAC) protein degrader targeting the wild-type androgen receptor (WT-AR) and mutant AR ligand-binding domain (AR-LBD).” PMID 40289067 ↗ Apr 2025 |